Skip to content

The role of omega-3 polyunsaturated fatty acids in the prevention of contrast-induced nephropathy (CIN) in post percutaneous coronary intervention (PCI) patients

Omega-3 in the prevention of contrast-induced nephropathy after percutaneous coronary intervention

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016041920441N4
Enrollment
80
Registered
2016-05-31
Start date
2016-03-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal disease. Contrast-induced nephropathy

Interventions

Intervention 1: Intervention: administration of omega-3, 12hr before percutaneous coronary intervention plus standard contrast-induced nephropathy preventive therapy (hydration). Intervention 2: Contr
Prevention
Intervention: administration of omega-3, 12hr before percutaneous coronary intervention plus standard contrast-induced nephropathy preventive therapy (hydration)
Control: just standard contrast-induced nephropathy preventive therapy (hydration)

Sponsors

Shiraz University of Medical Sciences, international branch
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included GFR more than 60 ml/min/1.73 m2; the ages of 18 to 80 years; patients undergoing elective PCI. Exclusion criteria: Pretreatment with N-acetyl cystein or intravenous vitamin C; sensitivity or tolerance to ASA or Clopidogrel or omega-3; sever adverse effects to drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Cystatin C. Timepoint: Baseline and 24 hours after PCI. Method of measurement: Kit.;Serum creatinine. Timepoint: Baseline and 24 hours after PCI. Method of measurement: Kit.

Secondary

MeasureTime frame
Contrast-induced nephropathy occurrence. Timepoint: 24 hrs after PCI. Method of measurement: Based on cystatin C.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Foroughinia

Shiraz University of Medical Sciences

farzanehforoughinia@yahoo.com+98 917 713 6095

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026